Casdin Capital 13F holdings, Q3 2020
Holdings as of September 30, 2020 · filings on SEC EDGAR · latest filing →
Casdin Capital disclosed 45 US equity positions worth $2.2bn in its Q3 2020 13F filing. The largest position was INVITAE CORP at 17.5% of the reported book, followed by BLFS and RLAY. Against the Q2 2020 filing, it opened 6 new positions, added to 13 and reduced 3 among the top 45 holdings.
What did Casdin Capital own in Q3 2020? Top 45 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q2 2020 |
|---|---|---|---|---|---|---|---|
| 1 | INVITAE CORP | 17.5% | $391.6m | 9,033,943 | 0% | held | |
| 2 | BLFS BIOLIFE SOLUTIONS INC | Healthcare | 7.6% | $169.0m | 5,840,107 | 20% | added |
| 3 | RLAY RELAY THERAPEUTICS INC | Healthcare | 7.3% | $162.2m | 3,808,894 | – | new |
| 4 | 2655787D BLUEPRINT MEDICINES CORP | 6.4% | $143.7m | 1,550,000 | 0% | held | |
| 5 | FATE FATE THERAPEUTICS INC | Healthcare | 5.5% | $121.9m | 3,050,000 | 0% | held |
| 6 | MYOKARDIA INC | 5.3% | $118.6m | 870,000 | 0% | held | |
| 7 | ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 4.0% | $90.3m | 620,000 | 13% | added |
| 8 | TWST TWIST BIOSCIENCE CORP | Healthcare | 3.4% | $76.0m | 1,000,000 | 0% | held |
| 9 | SRPT SAREPTA THERAPEUTICS INC | Healthcare | 3.3% | $74.4m | 530,000 | 0% | held |
| 10 | AGIO AGIOS PHARMACEUTICALS INC | Healthcare | 2.7% | $61.2m | 1,750,000 | 64% | added |
| 11 | RVMD REVOLUTION MEDICINES INC | Healthcare | 2.5% | $56.9m | 1,634,535 | 22% | added |
| 12 | GENERATION BIO CO | 2.2% | $49.8m | 1,611,214 | 0% | held | |
| 13 | BLUEBIRD BIO INC | 2.2% | $49.4m | 915,000 | -17% | reduced | |
| 14 | BNR BURNING ROCK BIOTECH LTD | 2.2% | $48.2m | 1,922,150 | 11% | added | |
| 15 | DNLI DENALI THERAPEUTICS INC | Healthcare | 2.1% | $46.9m | 1,310,000 | 0% | held |
| 16 | CDXS CODEXIS INC | Healthcare | 2.1% | $46.8m | 3,985,000 | -15% | reduced |
| 17 | CDNA CAREDX INC | Healthcare | 2.0% | $45.3m | 1,193,335 | 0% | held |
| 18 | PACB PACIFIC BIOSCIENCES CALIF IN | Healthcare | 2.0% | $44.4m | 4,500,000 | – | new |
| 19 | ONC BEIGENE LTD | Healthcare | 1.9% | $43.0m | 150,000 | 0% | held |
| 20 | ALLO ALLOGENE THERAPEUTICS INC | Healthcare | 1.6% | $35.6m | 945,000 | 51% | added |
| 21 | ADPT ADAPTIVE BIOTECHNOLOGIES COR | Healthcare | 1.6% | $34.7m | 713,125 | 0% | held |
| 22 | ADVERUM BIOTECHNOLOGIES INC | 1.3% | $28.3m | 2,750,000 | 47% | added | |
| 23 | MAGENTA THERAPEUTICS INC | 1.0% | $22.8m | 3,346,034 | 0% | held | |
| 24 | CRSP CRISPR THERAPEUTICS AG | Healthcare | 1.0% | $22.3m | 266,430 | 0% | held |
| 25 | GLOBAL BLOOD THERAPEUTICS IN | 1.0% | $21.8m | 395,000 | 32% | added | |
| 26 | AMYRIS INC | 1.0% | $21.6m | 7,390,000 | 38% | added | |
| 27 | CNST CONSTELLATION PHARMCETICLS I | 0.9% | $19.9m | 980,000 | 0% | held | |
| 28 | TSHA TAYSHA GENE THERAPIES INC | Healthcare | 0.8% | $18.4m | 820,440 | – | new |
| 29 | ALEC ALECTOR INC | Healthcare | 0.8% | $17.4m | 1,650,000 | 53% | added |
| 30 | DERMTECH INC | 0.8% | $17.1m | 1,428,572 | 0% | held | |
| 31 | ZLAB ZAI LAB LTD | Healthcare | 0.7% | $15.8m | 190,000 | 0% | held |
| 32 | BERKELEY LTS INC | 0.7% | $15.3m | 200,000 | – | new | |
| 33 | BRISTOL-MYERS SQUIBB CO | 0.6% | $14.1m | 6,250,000 | 112% | added | |
| 34 | FULC FULCRUM THERAPEUTICS INC | Healthcare | 0.5% | $11.4m | 1,441,176 | 0% | held |
| 35 | SGMOQ SANGAMO THERAPEUTICS INC | Healthcare | 0.5% | $10.2m | 1,080,000 | -26% | reduced |
| 36 | IOVA IOVANCE BIOTHERAPEUTICS INC | Healthcare | 0.4% | $9.5m | 290,000 | – | new |
| 37 | ILMN ILLUMINA INC | Healthcare | 0.4% | $9.3m | 30,000 | 0% | held |
| 38 | BLACK DIAMOND THERAPEUTICS I | 0.4% | $8.7m | 289,395 | 0% | held | |
| 39 | ORCHARD THERAPEUTICS PLC | 0.3% | $7.7m | 1,870,000 | 13% | added | |
| 40 | DYN DYNE THERAPEUTICS INC | Healthcare | 0.3% | $7.5m | 370,000 | – | new |
| 41 | TURNING POINT THERAPEUTICS I | 0.3% | $6.6m | 75,000 | 0% | held | |
| 42 | ORIC ORIC PHARMACEUTICALS INC | Healthcare | 0.3% | $6.3m | 251,515 | 0% | held |
| 43 | LEGN LEGEND BIOTECH CORP | Healthcare | 0.2% | $4.3m | 139,661 | 3% | added |
| 44 | STOK STOKE THERAPEUTICS INC | Healthcare | 0.2% | $4.0m | 120,000 | 0% | held |
| 45 | DECIPHERA PHARMACEUTICALS IN | 0.1% | $3.3m | 65,000 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.